A researcher wanted to understand the effect of a new drug on the cerebral blood
ID: 3207460 • Letter: A
Question
A researcher wanted to understand the effect of a new drug on the cerebral blood flow (CBF) in adult women. The researcher is concerned that CBF may drop to unsafe levels. An experiment was design to compare the CBF of individuals who took the new drug during the course of 1 week, and individuals who took a placebo.
Conduct the appropriate nonparametric test USING MATLAB to assess whether adults who take the new medicine have a reduction of CBF compared to those who did not. Conduct the test at the = 0.10 significance level.
Treatment Group 2.7 2.9 2.7 3.9 2.7 2.1 2.6 2.2 4.2 5.0 .7 5.3 Control Group 3.5 2.5 3.8 8.1 3.6 2.2 5.0 2.9 2.3 2.9 5.1Explanation / Answer
As matlab is a paid software , we shall not be able to use it. However , we shall provide the solution using the open source alternative R , the complete snippet is as follows
As these are independent 2 groups , we shall use a wilcox test . Also , the significance level would be 0.1, so if the calculated p value is less than 0.1 , we shall reject the null hypothesis in favor of alternate hypothesis
H0 : There is no difference in the average CBF value for the 2 groups
H1 : The treatment gorup has a signifcantly reduced average CBF value when compared with the control group
TG<-c(2.7, 2.9, 2.7, 3.9, 2.7, 2.1, 2.6, 2.2, 4.2 ,5.0 ,.7, 5.3)
CG<- c(3.5, 2.5, 3.8, 8.1, 3.6, 2.2, 5.0, 2.9, 2.3, 2.9, 5.1)
wilcox.test(TG,CG)
> wilcox.test(TG,CG)
Wilcoxon rank sum test with continuity correction
data: TG and CG
W = 51, p-value = 0.371
alternative hypothesis: true location shift is not equal to 0
as the p value is 0.371 which is greater than 0.1 , hence we fail to reject the null hypothesis and conclude that There is no difference in the average CBF value for the 2 groups and the new drug has no effect on the cbf values
Related Questions
drjack9650@gmail.com
Navigate
Integrity-first tutoring: explanations and feedback only — we do not complete graded work. Learn more.